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Loop diuretics are widely used in patients with heart and renal failure, as well as to treat hy-
pertension and peripheral edema. However, there are no randomized, controlled trials
(RCT) evaluating their long term safety, and several observational reports have indicated
adverse effects. We sought to evaluate the impact of loop diuretics on long term survival in
patients with suspected coronary artery disease, but without clinical heart failure, reduced
left ventricular ejection fraction or impaired renal function.
Method and Findings
From 3101 patients undergoing coronary angiography for suspected stable angina pectoris,
subjects taking loop diuretics (n=109) were matched with controls (n=198) in an attempted
1:2 ratio, using propensity scores based on 59 baseline variables. During median follow-up
of 10.1 years, 37.6% in the loop diuretics group and 23.7% in the control group died (log-
rank p-value 0.005). Treatment with loop diuretics was associated with a hazard ratio (95%
confidence interval) of 1.82 (1.20, 2.76), and the number needed to harm was 7.2 (4.1,
30.3). Inclusion of all 3101 patients using propensity score weighting and adjustment for nu-
merous covariates provided similar estimates. The main limitation is the potential of con-
founding from unmeasured patient characteristics.
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Conclusions
The use of loop diuretics in patients with suspected coronary artery disease, but without
systolic heart failure or renal impairment, is associated with increased risk of all-cause mor-
tality. Considering the lack of randomized controlled trials to evaluate long term safety of
loop diuretics, our data suggest caution when prescribing these drugs to patients without a
clear indication.
Introduction
Loop diuretics are widely used drugs, constituted mainly by the sulfonamide derivates furo-
semide, bumetanide and torsemide, which act on the thick ascending limb of the loop of
Henle. They are primarily prescribed to patients with acute and chronic heart failure with
signs of fluid overload, but also used in the treatment of acute and chronic renal failure, he-
patic failure, hypertension and peripheral edema. Loop diuretics have been a pillar in the
treatment of systolic heart failure for decades, and are strongly recommended in the current
heart failure guidelines from both the European Society of Cardiology and the American Col-
lege of Cardiology Foundation/American Heart Association [1, 2]. However, no large ran-
domized, controlled trials (RCTs) have been conducted to ensure long term efficacy and
safety [3–5], whereas several observational studies have associated long term treatment with
poor outcome in patients with systolic heart failure [6–12]. Epidemic overuse and substantial
toxicity have been described, particularly among the elderly [13, 14]. The large scale use is
confirmed by the high prescription rate in Norway (24.9/1000 of the total population, and
178/1000 among those aged 80–84 in 2012) [15]. Thus, there is reason to assume that a con-
siderable number of patients are treated with loop diuretics where no or other medications
would be superior.
The aim of the current study was to assess the relation between loop diuretics and mortality
in a cohort of suspected stable coronary artery disease (CAD) patients without systolic heart
failure or renal failure, i.e. patients most likely without a strong indication for receiving the
drug, using propensity score matching to reduce confounding.
Methods
Study population
The study population consisted of 4164 patients with suspected stable angina who underwent
coronary angiography at Haukeland University Hospital and Stavanger University Hospital,
Norway, from 1999 to 2004. A total of 2573 (61.8%) of these patients were included in the
Western Norway B Vitamin Intervention Trial (WENBIT) [16]. We excluded 718 patients
with either left ventricular ejection fraction (LVEF)<50%, a history of unspecified or right
heart failure, estimated glomerular filtration rate (eGFR)<60 mL/min/1.73 m2, aortic stenosis
or liver failure. Of the remaining 3446, 3101 had complete datasets with regard to all the covar-
iates we planned to use for propensity score matching. Of these, 126 patients were using loop
diuretics at discharge following the initial evaluation. Written, informed consent was obtained
from all participants. The study was approved by the Regional Committee for Medical and
Health Research Ethics, the Data Inspectorate, and the Norwegian Directorate of Health.
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Data collection, biochemical analyses and follow-up
Information on patients’ lifestyle and medical history was obtained from self-administered
questionnaires and verified by comparing to hospital records. The records of patients registered
as taking loop diuretics at baseline were additionally validated. Diabetes included both type 1
and 2. LVEF was obtained either by echocardiography or by ventriculography performed dur-
ing cardiac catheterization. Smokers included self-reported current smokers, those reporting
having quit within the last 4 weeks and subjects with plasma cotinine>85 nmol/L. A more de-
tailed characterization has been published previously [17]. Plasma was usually sampled a few
days before coronary angiography, and samples were prepared and immediately frozen at
-80°C. The patients were followed up through December 31, 2012 and the outcome data were
obtained by linking the unique personal identification numbers to the Cause of Death Registry
of Norway. Data on changes in drug prescriptions and patient compliance during follow-up
were not available.
Statistical analyses
Based on 59 baseline variables, including anthropometric, clinical and biochemical data, the
propensity score for loop diuretic usage was calculated using a logistic regression model for
each of the 3101 patients [18]. Patients receiving loop diuretics (treated) and controls were
matched on the logit of the propensity score, using calipers of width equal to 0.2 times the stan-
dard deviation of the logit of the propensity score. We used nearest neighbour matching at-
tempting a 1:2 ratio, with no interactions included. 17 patients on loop diuretics could not be
matched (S1 Fig). Balance between the treatment and control groups was assessed by un-
weighted standardized mean differences, variance ratios between treated and controls, histo-
grams and jitter plots of propensity score distribution and visual inspection of QQ plots. The
null hypothesis of equality of variances for continuous variables was estimated following an F-
distribution with 107 and 195 degrees of freedom [19]. The 2.5 and 97.5 percentiles were 0.61
and 1.39, respectively. Post-matching continuous variables are shown as means (standard devi-
ation [SD]) and medians (interquartile range [IQR]) and categorical variables as percentages.
Statistical differences between the groups were tested with independent T-tests, Wilcoxon
signed-rank tests and Chi-square tests. All-cause mortality was initially explored with a
Kaplan-Meier plot and log-rank test. Number needed to harm was calculated as the inverse of
the attributable risk (incidence of death in treated minus controls) and the 95% confidence in-
tervals (CI) by using the simple Wald method. Cox regression analyses were conducted to cal-
culate hazard ratios (HRs), both using crude data and extensive adjustment for covariates. Not
all matching variables were included in these analyses, in order to avoid collinearity (e.g. hyper-
tension but not systolic blood pressure). A time dependent covariate was used to test for non-
proportional hazards. Propensity score weighted Cox regression analyses were performed in
the entire cohort of 3101 patients in a similar manner. In order to assess the magnitude of po-
tential residual confounding, sensitivity analyses were performed using the method described
by Lin et al [20]. All analyses and plots were done using R (version 3.1.1). For propensity
matching and weighting we used the MatchIt [21, 22] and Twang packages, respectively.
Results
Baseline characteristics
109 matched pairs were formed, of which 89 pairs consisted of one patient receiving loop di-
uretics and two controls, and 20 pairs consisting of one patient using loop diuretics and one
control. Table 1 shows the post-matching baseline characteristics of the treatment and control
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Table 1. Baseline characteristics after matching.
Controls Loop diuretics P-value
N 198 109
Age (years) 64.9 (9.2) 65 (11) 0.95
Sex (male %) 114 (57.6) 55 (50.5) 0.28
WENBIT participation (%) 95 (48) 57 (52.3) 0.55
Smoking (%) 47 (23.7) 31 (28.4) 0.44
Medical history (%)
Hypertension 124 (62.6) 75 (68.8) 0.34
Diabetes 25 (12.6) 16 (14.7) 0.74
Family history of CAD 58 (29.3) 35 (32.1) 0.70
Acute myocardial infarction 93 (47) 52 (47.7) 1.00
PCI 34 (17.2) 23 (21.1) 0.49
CABG 23 (11.6) 13 (11.9) 1.00
Peripheral vascular disease 20 (10.1) 13 (11.9) 0.76
Cerebrovascular disease 30 (15.2) 17 (15.6) 1.00
Active cancer 4 (2) 3 (2.8) 0.99
Cured cancer 12 (6.1) 10 (9.2) 0.44
DVT or vein surgery 8 (4) 5 (4.6) 1.00
Pulmonary disease 45 (22.7) 27 (24.8) 0.79
Kidney disease 2 (1) 1 (0.9) 1.00
Atrial fibrillation 32 (16.2) 19 (17.4) 0.90
Clinical and paraclinical
findings
Dyspnea (NYHA class) (%)
0–1 116 (58.6) 62 (56.9) 0.87
2 63 (31.8) 34 (31.2) 1.00
3 19 (9.6) 13 (11.9) 0.66
4 0 0
Body mass index (kg/m2) 28.2 (5.3) 28.4 (5) 0.76
ECG rythm (sinus %) 178 (89.9) 96 (88.1) 0.76
LVEF (%) 66.4 (8.1) 65.8 (8.8) 0.54
Angiographic extent of CAD
(%)
0-vessel disease 60 (30.3) 31 (28.4) 0.83
1-vessel disease 46 (23.2) 23 (21.1) 0.78
2-vessel disease 46 (23.2) 30 (27.5) 0.49
3-vessel disease 46 (23.2) 25 (22.9) 1.00
Systolic BP (mmHg) 143 (19) 143 (21) 0.95
Diastolic BP (mmHg) 80.9 (10) 81.2 (11) 0.82
Blood parameters
eGFR (mL/min/1.73 m2) 85.5 (13) 84.9 (15) 0.76
Uric acid (umol/L) 386 (85) 388 (96) 0.88
Hemoglobin (g/dL) 14.1 (1.3) 13.9 (1.3) 0.21
Potassium (mmol/L) 4.24 (0.32) 4.23 (0.32) 0.72
Sodium (mmol/L) 142 (2.4) 142 (2.3) 0.52
C-reactive protein (mg/L) 2.2 (3.8) 3.06 (3.6) 0.04
HbA1c (%) 6.1 (1.3) 6.17 (1.2) 0.63
Glucose (mmol/L) 248 (60) 257 (66) 0.28
Platelet count (10^9/L) 6.41 (2.4) 6.6 (2.1) 0.47
(Continued)
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groups. The mean (SD) age was 64.9 (9.8) years and 55.0% were males. The most prevalent
pre-existing medical conditions were hypertension (64.8%) and acute myocardial infarction
(AMI) (47.2%), and almost three quarters had angiographic evidence of CAD. About three
quarters were treated with beta-blockers, statins and aspirin. Baseline characteristics before
matching are shown in S1 Table.
Balance analyses
Fig 1 displays the absolute standardized mean differences between all matching covariates be-
fore and after matching. Post matching, the differences for most covariates were0.1, but
Table 1. (Continued)
Controls Loop diuretics P-value
N 198 109
WBC (10^9/L) 7.41 (2.2) 7.5 (1.9) 0.72
Triglycerides (mmol/L) 1.52 (1.1) 1.4 (0.86) 0.98
Low density lipoprotein (mmol/
L)
3.04 (0.95) 3.07 (1.1) 0.80
Apolipoprotein A1 (g/L) 1.37 (0.28) 1.38 (0.29) 0.69
Apolipoprotein B (g/L) 0.892 (0.23) 0.897 (0.24) 0.86
Troponin T (ng/L) 6 (9.8) 7 (10) 0.75
Discharge medication (%)
Aspirin 152 (76.8) 84 (77.1) 1.00
ADP-receptor inhibitor 24 (12.1) 11 (10.1) 0.73
Warfarin 17 (8.6) 12 (11) 0.62
ACEI or/and ARB 101 (51) 57 (52.3) 0.92
Beta-blocker 150 (75.8) 82 (75.2) 1.00
Digoxin 15 (7.6) 11 (10.1) 0.59
Spironolactone 5 (2.5) 2 (1.8) 1.00
Thiazide 18 (9.1) 8 (7.3) 0.75
Calcium antagonist 57 (28.8) 38 (34.9) 0.33
Nitrate 55 (27.8) 34 (31.2) 0.62
Statin 148 (74.7) 86 (78.9) 0.50
Insulin 7 (3.5) 4 (3.7) 1.00
Metformin 12 (6.1) 8 (7.3) 0.85
Sulfonylurea 11 (5.6) 6 (5.5) 1.00
COPD-medication 28 (14.1) 16 (14.7) 1.00
NSAID 10 (5.1) 6 (5.5) 1.00
Corticosteroid 13 (6.6) 7 (6.4) 1.00
Antidepressant 16 (8.1) 9 (8.3) 1.00
Antipsychotic 2 (1) 2 (1.8) 0.93
Continuous variables are shown as means (standard deviation) and medians (interquartile range) and
categorical variables as numbers (percentage). Abbreviations: WENBIT = WEstern Norway B-vitamin Trial;
CAD = coronary artery disease; PCI = percutaneous coronary intervention; CABG = coronary artery bypass
graft; PVD = peripheral vascular disease; DVT = deep venous thrombosis; NYHA = New York Heart
Association; BP = blood pressure; eGFR = estimated glomerular filtration rate; HbA1c = glycated
hemoglobin; WBC = white blood cell count; ACEI = angiotensin converting enzyme inhibitor;
ARB = angiotensin receptor blocker; COPD = chronic obstructive pulmonary disease; NSAID = non-steroid
anti-inflammatory drug.
doi:10.1371/journal.pone.0124611.t001
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Fig 1. Absolute standardized mean differences for baseline characteristics before and after matching.
Squares: Before matching. Diamonds: after matching.
doi:10.1371/journal.pone.0124611.g001
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somewhat higher for C-reactive protein (CRP) levels with a differences of 0.149. The propensi-
ty scores were evenly distributed in both groups (S1 and S2 Figs), and the ratios of variances of
treated vs. controls were within the expected 95% CIs for equality for all continuous covariates,
except for age with a ratio of 1.40 (S2 Table).
Loop diuretics and all-cause mortality
During a follow-up time of median (IQR) 10.1 (2.2) years, 41 (37.6%) of the treated patients
died, as compared to 47 (23.7%) in the control group (p for log-rank test 0.005). Fig 2 shows a
Kaplan Meier survival plot comparing the two groups. The unadjusted hazard ratio (HR) (95%
CI) was 1.82 (1.20, 2.76). The number needed to harm was 7.2 (4.1, 30.3). Further adjusting for
baseline covariates did not substantially attenuate the results (Table 2). Inclusion of all 3101 pa-
tients using propensity score weighting yielded similar estimates.
Loop diuretics and cardiovascular and non-cardiovascular mortality
Cardiovascular death occurred in 17 (15.6%) patients using loop diuretics and in 23 (11.6%) of
the controls (HR 1.55 (0.83, 2.90), p = 0.17). Correspondingly, non-cardiovascular deaths oc-
curred in 24 (22.0%) and 24 (12.1%) patients (HR 2.07 (1.17, 3.65), p = 0.003). Adjustment for
confounders resulted in similar point estimates.
Fig 2. Kaplan-Meier plot showing survival curves for patients using loop diuretics andmatched
controls. The p-value for difference was calculated using log-rank test.
doi:10.1371/journal.pone.0124611.g002
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Sensitivity analysis
Fig 3 shows how an unmeasured, dichotomous confounder could possibly explain the elevated
risk associated with using loop diuretics. A single unmeasured confounder (e.g. frailty or dia-
stolic heart failure), if present in 100% of the patients receiving the drug and merely 5% of the
controls, could account for the observed risk if it was associated with a HR for all-cause mortal-
ity of about 1.2. However, a more realistic distribution of an unknown confounder would for
example be 20% in the control group and 40% in the loop diuretic group, a situation in which
the unknown confounder must confer a HR of 2.2.
Discussion
In this observational, long term cohort of patients with suspected stable CAD, but without sys-
tolic heart failure or renal failure, subjects treated with loop diuretics had an almost twofold
higher risk of all-cause death when compared to propensity matched controls. The number
needed to harm was 7.2. Extensive adjustment did not substantially alter the results, and the
findings were consistent also in the overall cohort using propensity score weighting.
Existing evidence
Loop diuretics form the cornerstone in the treatment of systolic heart failure and hold strong
recommendations in current guidelines [1, 2]. Yet, only a few, small RCTs investigating the im-
pact of loop diuretics on survival in these patients have been conducted, the most recent almost
30 years ago [23–25]. The results were pooled in a meta-analysis with altogether 221 patients,
including totally 15 fatalities during follow-up times ranging from a few weeks to one year, and
showed significant improvement in survival [26]. In contrast, several large, more recent, obser-
vational studies have found increased mortality associated with the use of loop diuretics among
patients with chronic systolic heart failure [6–9], also supported by a potential dose-response
Table 2. Cox regression survival models.
Unadjusted model Adjusted model*
Type of mortality Years of follow up N at risk N events Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Propensity matched cohort
All-cause 10.1 307 88 1.82 (1.20, 2.76) 0.005 1.87 (1.15, 3.05) 0.011
CVD 10.1 307 40 1.55 (0.83, 2.90) 0.173 1.29 (0.59, 2.83) 0.52
Non-CVD 10.1 307 48 2.07 (1.18, 3.65) 0.012 2.01 (1.09, 3.71) 0.025
Propensity weighted cohort
All-cause 10.4 3101 517 1.86 (1.58, 2.20) <0.001 1.59 (1.32, 1.93) <0.001
CVD 10.4 3101 207 2.12 (1.65, 2.71) <0.001 1.69 (1.25, 2.29) <0.001
Non-CVD 10.4 3101 310 1.69 (1.36, 2.11) <0.001 1.47 (1.13, 1.89) 0.003
Abbreviations: CVD cardiovascular disease.
*Covariates: age, sex, study site, participation in the WENBIT study, smoking, family history of coronary heart disease, medical history (hypertension,
diabetes, acute myocardial infarction, percutaneous intervention, coronary artery bypass surgery, peripheral vascular disease, cerebrovascular disease,
cured cancer, active cancer (not in the cardiovascular mortality analyses due to failure of the model to converge), deep vein thrombosis or vein surgery,
pulmonary disease, atrial fibrillation, dyspnea grade 0–4), measured parameters at baseline (body mass index, ECG rhythm, left ventricular ejection
fraction, number of coronary vessels with >50% stenosis), laboratory values (estimated glomerular filtration rate, uric acid, hemoglobin, potassium,
sodium, C-reactive protein, glycated hemoglobin, low density lipoprotein, troponin T), medication (aspirin, adenosine diphosphate receptor inhibitor,
warfarin, angiotensin converting enzyme inhibitor and/or angiotensin receptor blocker, beta-blocker, digoxin, spironolactone, thiazide, calcium antagonist,
nitrate, statin, insulin, metformin, sulfonylurea, treatment for chronic obstructive pulmonary disease, non-steroid anti-inflammatory drug, corticosteroid,
antidepressant, antipsychotic), and baseline revascularization.
doi:10.1371/journal.pone.0124611.t002
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relationship [10–12]. In diastolic heart failure, a randomized pilot investigation in elderly pa-
tients found improvements in hemodynamic parameters three months after withdrawal of fu-
rosemide [27]. In acute heart failure the results from observational data are more ambiguous
[28–30]. An RCT found no difference between a low-dose vs. high-dose strategy after 60 days
[31], while a small RCT showed increased risk of adverse events in patients treated with contin-
uous vs. bolus furosemide [32]. As for treatment of hypertension, a Cochrane review did not
find sufficient evidence to recommend the use of loop diuretics, and noted the paucity of data
available [4], whereas a recent observational study showed increased mortality in hypertensive
patients with atrial fibrillation treated with loop diuretics [33]. In renal failure patients loop di-
uretics are frequently prescribed, but only low quality RCTs have been conducted and the ef-
fects are questionable [34]. Further, the drugs are also used to treat peripheral edema of various
etiologies. A Dutch community based study reported high prevalence of “off label” use amongst
elderly (16% for hypertension, 8% for peripheral edema and 8% for unknown reasons) [14].
Our results are coherent with earlier reports of increased mortality in chronic systolic heart
failure patients treated with loop diuretics. The increased risk of non-cardiovascular mortality
has, to our knowledge, not previously been described. Only one earlier study reported non-car-
diovascular mortality and found no association with loop diuretics.[8]
Possible pathomechanisms
Long-term use of loop diuretics may lead to a plethora of possible adverse effects. Importantly,
furosemide, the most commonly used substance, has a very erratic absorption [35]. The risk of
hypokalemia, associated with potentially lethal arrhythmias, is well recognized [36], and
Fig 3. Sensitivity plot showing how high the hazard ratio of a single, unknown, dichotomous
confounder would have to be, at different levels of distribution among patients using loop diuretics
and controls, to fully explain the observed risk of death associated with loop diuretics.
doi:10.1371/journal.pone.0124611.g003
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potassium supplementation to loop diuretics is associated with improved survival [37]. In the
elderly, hyponatremia and hypovolemia are common side effects, being related to several out-
comes which again are associated with poor survival, such as osteoporosis, hypotension, confu-
sion and brain damage [13]. Polypharmacy is becoming increasingly prevalent, and loop
diuretics carry a significant risk of drug-drug interactions [38]. They are sometimes combined
with a thiazide to treat diuretic resistance, albeit with the risk of severe side effects [39]. With
the emergence of combination pills to treat hypertension, this might also happen unintention-
ally [13]. It is interesting to note the potential paradoxical effect of loop diuretics in systolic
heart failure; increased diuresis leads to hypovolemia which induces renin-angiotensin system
activation and sympathetic stimulation [40]—pathways which when blocked are the only prov-
en way to reduce systolic heart failure mortality. Accordingly, an increased risk of mortality
was found in rats randomized to furosemide, compared to placebo or the combination of furo-
semide and ramipril [41].
Higher risk of renal cell carcinoma is described in patients treated with loop and thiazide di-
uretics [42], and furosemide-induced DNA damage has been observed in mice [43]. However,
to our knowledge, no clear association between loop diuretics and carcinogenesis has been es-
tablished. Given the increased risk of both cardiovascular and non-cardiovascular mortality,
one can speculate that the sum of circulatory and metabolic changes caused by loop diuretics
might aggravate the course of other diseases, irrespective of etiology. However, such adverse ef-
fects likely must have developed during follow-up, given the extensive baseline matching.
Strengths and limitations
When analysing a single baseline variable, propensity score matching is one of the most robust
ways of approaching observational data in order to reduce confounding and assess possible
causality [44]. In this study, acceptable balance between treated and controls was achieved, ac-
cording to several tests [19]. Only CRP was slightly higher in treated patients. Consistency
across both different propensity score methods and model selections support the potential of a
true causal relationship. Regardless of rigorous statistical efforts, residual confounding almost
certainly exists. However, sensitivity analyses show that such a confounder (or group of con-
founders) must either be almost perfectly asymmetrically distributed between the groups or
confer a very high HR for mortality if it were to explain the findings by confounding alone.
An important limitation of the current work is the lack of information about left ventricular
diastolic function and clinical signs of fluid overload. We did, however, take into account con-
ditions strongly associated with diastolic heart disease, such as obesity, diabetes, hypertension,
age and atrial fibrillation. Other limitations include the lack of data on the duration of treat-
ment prior to study inclusion, the type and dose of loop diuretic, and drug compliance during
follow-up.
Clinical implications
No long-term RCTs of loop diuretics have been conducted. Hence, this and other recent obser-
vational studies provide the best current evidence base and suggest potential harm by such
treatment [6–12]. Importantly, due to the lack of RCTs, the evidence needed to reject the hy-
pothesis of clinical benefit is less strict than would otherwise be the case. According to the
maxim ‘primum non nocere’ our study argues against the use of loop diuretics in patients with-
out a strong indication. Indeed, the recently coined term ‘Morbus Diureticus’ [13], used to de-
scribe the perils of epidemic overuse of diuretics in the elderly, may be eerily accurate.
Loop Diuretics and Mortality
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Conclusions
In patients with suspected coronary artery disease but without systolic heart failure or renal
failure, use of loop diuretics is associated with all-cause mortality. In such patients, without
clinical signs of fluid overload, discontinuation of loop diuretics should be considered.
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S1 Fig. Jitter plots of the distributions of propensity scores before and after matching
among patients treated with loop diuretics (treatment units) and controls, illustrating
which patients were excluded from the final analyses due to inadequate matching.
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